Ajay Vallakati1, Siddharth Reddy2, Mark E Dunlap2, David O Taylor2. 1. From the Division of Cardiovascular Diseases, The Ohio State University Wexner Medical Center, Columbus (A.V.); Division of Cardiovascular Diseases, Metrohealth Medical Center, Case Western Reserve University, Cleveland, OH (S.R., M.E.D.); and Department of Cardiovascular Medicine, Heart and Vascular Institute Cleveland Clinic, Cleveland, OH (D.O.T.). ajayvhs@gmail.com. 2. From the Division of Cardiovascular Diseases, The Ohio State University Wexner Medical Center, Columbus (A.V.); Division of Cardiovascular Diseases, Metrohealth Medical Center, Case Western Reserve University, Cleveland, OH (S.R., M.E.D.); and Department of Cardiovascular Medicine, Heart and Vascular Institute Cleveland Clinic, Cleveland, OH (D.O.T.).
Abstract
BACKGROUND: Although various studies revealed the beneficial effects of statins in post-cardiac transplant patients, these were relatively small and low-powered studies. We performed a meta-analysis of published studies to evaluate the role of statins in post-cardiac transplant patients, specifically examining the effects on hemodynamically significant/fatal graft rejection, coronary vasculopathy, terminal cancer, and overall survival. METHODS AND RESULTS: We searched PubMed, Cochran CENTRAL, and Web of Science databases using the search terms "cardiac transplant" or "heart transplant," and "statin" for a literature search. A random-effects model with Mantel-Haenszel method was used to pool the data. We identified 10 studies, 4 randomized controlled trials, and 6 nonrandomized studies, which compared outcomes in heart transplant recipients undergoing statin therapy to statin-naive patients. A pooled analysis of 9 studies reporting mortality revealed that the use of statins was associated with significant reduction in all-cause mortality (odds ratio, 0.26; 95% confidence interval, 0.20-0.35; P<0.0001). Statins also decreased the odds of hemodynamically significant/fatal rejection (odds ratio, 0.37; 95% confidence interval, 0.21-0.65; P=0.0005), incidence of coronary vasculopathy (odds ratio, 0.33; 95% confidence interval, 0.16-0.68; P=0.003), and terminal cancer (odds ratio, 0.30; 95% confidence interval, 0.15-0.63; P=0.002). CONCLUSIONS: The evidence from a pooled analysis suggests that statins improve survival in heart transplant recipients. Statins may prevent fatal rejection episodes, decrease terminal cancer risk, and reduce the incidence of coronary vasculopathy. Additional prospective studies are needed to further investigate and explain this association.
BACKGROUND: Although various studies revealed the beneficial effects of statins in post-cardiac transplant patients, these were relatively small and low-powered studies. We performed a meta-analysis of published studies to evaluate the role of statins in post-cardiac transplant patients, specifically examining the effects on hemodynamically significant/fatal graft rejection, coronary vasculopathy, terminal cancer, and overall survival. METHODS AND RESULTS: We searched PubMed, Cochran CENTRAL, and Web of Science databases using the search terms "cardiac transplant" or "heart transplant," and "statin" for a literature search. A random-effects model with Mantel-Haenszel method was used to pool the data. We identified 10 studies, 4 randomized controlled trials, and 6 nonrandomized studies, which compared outcomes in heart transplant recipients undergoing statin therapy to statin-naive patients. A pooled analysis of 9 studies reporting mortality revealed that the use of statins was associated with significant reduction in all-cause mortality (odds ratio, 0.26; 95% confidence interval, 0.20-0.35; P<0.0001). Statins also decreased the odds of hemodynamically significant/fatal rejection (odds ratio, 0.37; 95% confidence interval, 0.21-0.65; P=0.0005), incidence of coronary vasculopathy (odds ratio, 0.33; 95% confidence interval, 0.16-0.68; P=0.003), and terminal cancer (odds ratio, 0.30; 95% confidence interval, 0.15-0.63; P=0.002). CONCLUSIONS: The evidence from a pooled analysis suggests that statins improve survival in heart transplant recipients. Statins may prevent fatal rejection episodes, decrease terminal cancer risk, and reduce the incidence of coronary vasculopathy. Additional prospective studies are needed to further investigate and explain this association.
Authors: Małgorzata Sobieszczańska-Małek; Jerzy Korewicki; Krzysztof Komuda; Małgorzata Karczmarz; Sylwia Szymańska; Alicja Cicha-Mikołajczyk; Paweł Bekta; Adam Parulski; Maciej Pronicki; Wiesława Grajkowska; Grzegorz Małek; Przemysław Leszek; Maria Kaczorowska; Mariusz Kuśmierczyk; Tomasz Zieliński Journal: Ann Transplant Date: 2017-11-17 Impact factor: 1.530
Authors: H W Grievink; V Smit; B W Huisman; P Gal; Y Yavuz; C Klerks; C J Binder; I Bot; J Kuiper; A C Foks; M Moerland Journal: Front Immunol Date: 2022-09-15 Impact factor: 8.786
Authors: Rabea Asleh; Alexandros Briasoulis; Naveen L Pereira; Barry A Boilson; Brooks S Edwards; Rosalyn Adigun; Simon Maltais; Richard C Daly; Amir Lerman; Sudhir S Kushwaha Journal: ESC Heart Fail Date: 2018-07-17